Recent advances in S-adenosyl-L-homocysteine hydrolase inhibitors and their potential clinical applications

Bibliography

• YUAN CS, LIU, S, WNUK SF, ROBINS MJ, BORCHARDT RT: Design and synthesis of S-adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents. In: Advances in Antiviral Drug Design (Volume 2). De Clercq E (Ed.), JAI Press, Inc., London, UK (1996):41–88.
   Google Scholar
• •Comprehensive review on SAH hydrolase as a target for antiviral drug design: from rationale to drug synthesis.
   Google Scholar
• DE CLERCQ E: S-adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents. Biochem. Pharmacol. (1987) 36:2567–2575.
   PubMed Web of Science ®Google Scholar
• HENDERSON DM, HANSON S, ALLEN T et al.: Cloning of the gene encoding Leishmania donovani S-adenosylh-omocysteine hydrolase, a potential target for antipara-sitic chemotherapy. Mol. Biochem. Parasitol. (1992) 53(1-2):169–183.
   PubMed Web of Science ®Google Scholar
• GLAZER RI, KNODE MC, TSENG C, HAINES DR, MARQUES VE: 3-Deazaneplanocin A: a new inhibitor of S-adenosylhomocysteine synthesis and its effects in human colon carcinoma cells. Biochem. Pharmacol. (1986) 35:4523–4527.
   PubMed Web of Science ®Google Scholar
• LAMBERT LE, FRONDORF KA, BERLING JS, WOLOS JA: Effects of an S-adenosyl-L-homocysteine hydrolase inhibitor on murine macrophage activation and function. Immunopharmacology (1995) 29:121–127.
   PubMed Web of Science ®Google Scholar
• WOLOS JA, FRONDORF KA, ESSER RE: Immunosuppres-sion mediated by an inhibitor of S-adenosyl-L-homocy-steine hydrolase. j Immunol. (1993) 151:526–534.
   PubMed Web of Science ®Google Scholar
• ••One of the earliest articles to described the effectiveness ofSAH hydrolase inhibitors as immunosuppressants in animal models.
   Google Scholar
• YUAN CS, SASO YH, LAZARIDES E: Unpublished data.
   Google Scholar
• UELAND PM, REFSUM H: Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease and drug therapy. J. Lab. Clin. Med. (1989) 114:473–501.
   PubMed Web of Science ®Google Scholar
• HU Y, KOMOTO J, HUANG Y et al.: Crystal structure of S-adenosylhomocysteine hydrolase from rat liver. Biochemistry (1999) 38:8323–8333.
   Google Scholar
• •For the first time, the x-ray structure of SAH hydrolase was determined in the absence of an inhibitor. The enzyme exists with its binding site in the 'open' form.
   Google Scholar
• TUNER MA, YUAN CS, BORCHARDT RT, HERSHFIELD MS, SMITH GD, HOWELL PL: Structure determination of selenomethionyl S-adenosylhomocysteine hydrolase using data at a single wavelength. Nature Struct. Biol. (1998) 5:369–376.
   PubMedGoogle Scholar
• •For the first time, the x-ray structure of SAH hydrolase was determined in the presence of a Type I inhibitor of the enzyme. The inactivated enzyme exists in a 'closed' form at the substrate binding site.
   Google Scholar
• KELLER BT, BORCHARDT RT: Inhibition of S-adenosylmethionine-dependent transmethylation as an approach to the development of antiviral agents. In: Antiviral Drug Development De Clercq E, Walker RT (Eds.), Plenum Press, New York, USA (1988):123–138.
   Google Scholar
• KONARSKA MM, PADGETT RA, SHARP PA: Recognition of cap structure in splicing in vitro of mRNA precur-sors. Cell (1984) 38:731–736.
   PubMed Web of Science ®Google Scholar
• KRUG RM, BRONI BA, BOULOY M: Are the 5'-ends ofinfluenza viral mRNA synthesized in vivo donated by host mRNA? Cell (1979) 18:329–334.
   PubMed Web of Science ®Google Scholar
• GLUANOWSKI A, MONTGOMERY JA, CANTONI GL, CHIANG PK: Adenosine analogs as substrates and inhibitors of S-adenosylhomocysteine hydrolase. Biochemistry (1981) 20:110–115.
   PubMedGoogle Scholar
• BORCHARDT RT, KELLER BT, PATEL-THOMBRE U: Neplanocin A, a potent inhibitor of S-adenosylhom-ocysteine hydrolase and of vaccinia virus multiplica-tion in mouse L-929 cells. J. Biol. Chem. (1984) 259:4353–4358.
   PubMed Web of Science ®Google Scholar
• HUGGINS J, ZHANG ZX, DAVIS K, COULOMBE RA: Inhibi-tion of Ebola virus by S-adenosylhomocysteine hydrolase inhibitors. Antiviral Research, Eighth Interna-tional Conference on Antiviral Research, Santa Fe, New Mexico (1995). Abstract A301.
   Google Scholar
• HUGGINS J, ZHANG ZX, BRAY M: Antiviral drug therapy of fllovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. J. Infect. Dis. (1999) 179:S240–247.
   Web of Science ®Google Scholar
• ••Data show that SAH hydrolase inhibitors were effectiveagainst Ebola virus infection. SAH hydrolase inhibitors are the only known agents having antiviral activity against Ebola viral infections.
   Google Scholar
• DE CLERCQ E: Carbocyclic adenosine analogs as S-adenosylhomocysteine hydrolase inhibitors and antiviral agents: recent advances. Nucleosides Nucleo-tides (1998) 17:625–634.
   PubMedGoogle Scholar
• MEHDI S, JARVI ET, KOEHL JR, MCCARTHY JR, BEY P: The mechanism of inhibition of S-adenosyl-L-homocy-steine hydrolase by fluorine-containing adenosine analogs. J. Enzym. Inhib. (1990) 4:1–13.
   PubMedGoogle Scholar
• YUAN CS, YEH J, LIU S, BORCHARDT RT: Mechanism of inactivation of S-adenosylhomocysteine hydrolase by (Z)-4',5'-didehydro-5'-deoxy-5'-fluoroadenosine. J. Biol. Chem. (1993) 268:17030–17037.
   PubMed Web of Science ®Google Scholar
• PRAKASH NJ, DAVIS GF, JARVI ET, EDWARDS ML, MCCARTHY JR, BOWLIN TL: Antiretroviral activity of mechanism-based irreversible inhibitors of S-adenosylhomocysteine hydrolase. Life Sci. (1992) 50:1425–1435.
   PubMed Web of Science ®Google Scholar
• YUAN CS, WNUK SF, ROBINS MJ, BORCHARDT RT: A novel mechanism-based inhibitor (6'-bromo-5', 6'-didehydro-6'-deoxy-6'-fluorohomoadenosine) that covalently modifies human placental S-adenosylhom-ocysteine hydrolase. J. Biol. Chem. (1998) 273:18191–18197.
   PubMedGoogle Scholar
• •Identified the first Type II inhibitor of SAH hydrolase that employs the 'hydrolytic activity' of the enzyme.
   Google Scholar
• WOLOS JA, FRONDORF KA, BABCOCK GF, STRIPP SA, BOWLIN TL: Immunomodulation by an inhibitor of S-adenosyl-t-homocysteine hydrolase: inhibition of in vitro and in vivo allogeneic responses. Cell Immunol (1993) 149:402–408.
   PubMed Web of Science ®Google Scholar
• WOLOS JA, FRONDORF KA, DAVIS GF, JARVI ET, MCCARTHY JR, BOWLIN TL: Selective inhibition of T cell activation by an inhibitor of S-adenosyl-t-homocy-steine hydrolase. j Immunol (1993) 150:3264–3273.
   PubMed Web of Science ®Google Scholar
• ••For the first time it was shown that SAH hydrolase inhibitorsselectively inhibited T-cell activation but had no effect on B-cells. Inhibition of T-cell activation by the enzyme inhibitor is related to inhibition of IL-2 production and IL-2R expression.
   Google Scholar
• BOUSHEY CJ, BERESFORD SA, OMENN GS, MOTULSKY AG: A quantitative assessment of plasma homocys-teine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA (1995) 274:1049–1057.
   Google Scholar
• MOGHADASIAN MH, MCMANUS BM, FROHLICH JJ: Homocyst(e)ine and coronary artery disease. Clinical evidence and genetic and metabolic background. Arch. Intern. Med (1997) 157:2299–2308.
   PubMedGoogle Scholar
• BELLAMY MF, MCDOWELL IF: Putative mechanisms forvascular damage by homocysteine. J. Inherit. Metab. Dis. (1997) 20:307–315.
   PubMedGoogle Scholar
• TOOLE JF: Vitamin intervention for stroke prevention (VISP). Stroke (1997) 28:2107–2108.
   Google Scholar
• ••The specific design of a double-blind, randomised,placebo-controlled, multicentre clinical trial (VISP) including patient number, patient eligibility doses of vitamins, end points, and time lines is described.
   Google Scholar